Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: The Southwest Oncology Group (SWOG) experience

Blood

Volumn 116, Issue 13, 2010, Pages 2224-2228

  Medeiros, Bruno C ^a   Othus, Megan ^a,b   Fang, Min ^c,d,e   Roulston, Diane ^f   Appelbaum, Frederick R ^c,e  

^a STANFORD UNIVERSITY   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; FEMALE; HUMAN; KAPLAN MEIER METHOD; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMAL KARYOTYPE; MONOSOMY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

EID: 77957715843     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-270330     Document Type: Article

References (19)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96(13):4075-4083.
3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia group B (CALBG 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
4. Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
5. Granada I, Brunet S, Hoyos M, et al. Prognostic value of monosomal karyotype in patients with primary acute myeloid leukemia on behalf of Spanish CETLAM Group [abstract]. Blood. 2009; 114(22):Abstract 1003.
6. Ahn HK, Kim DH, Park S, et al. Monosomy karyotype in acute myeloid leukemia predicts adverse treatment outcome with low complete remission rate and worse event-free and overall survival, and associates with high functional activity of multidrug resistance (MDR) [abstract]. Blood. 2009;114(22):Abstract 3112.
7. Perrot A, Luquet I, Pigneux A, et al. Prognostic value of the 'monosomal karyotype' entity in elderly patients with AML: a GOELAMS study of 186 patients with unfavourable cytogenetic abnormalities[abstract]. Blood. 2009;114(22):Abstract 1577.
8. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88(8):2841-2851.
9. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood. 1998;91(10):3607-3615.
10. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New Engl J Med. 1998;339(23):1649- 1656.
11. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98(12):3212-3220.
12. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100(12):3869-3876.
13. Petersdorf SH, Rankin C, Head DR, et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Am J Hematol. 2007;82(12):1056-1062. (Pubitemid 350209846)
14. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: an International Intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood. 2009;114 (22):Abstract 790.
15. Chauncey TR, Gundacker H, Shadman M, et al. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2010;148(1):48-58.
16. ISCN (2009). An international system for human cytogenetic nomenclature. Shaffer LG, Slovak ML, Campbell LJ, eds. S. Krager; Basel, Switzerland.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;52(282):457-481.
18. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc, Series B. 1972;34(2)187-220.
19. Grimwade J, Hills R, Moorman AV, et al. Refinement of cytogenetic classification in AML: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5635 younger adults treated in the UK MRC trials [abstract]. Haematologica. 2008;93(s1):34. Abstract 0533.